Please assess the completion status of the following clinical trial:

Trial Title: Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of chronic myelogenous leukemia (CML) documented by cytogenetic and molecular analyses at Johns Hopkins~  * Philadelphia chromosome (Ph)-positive or -negative CML~    * Ph-negative CML allowed with presence of either:~      * BCR-ABL rearrangement (on molecular, fluorescent in situ hybridization, or polymerase chain reaction analyses)~     * p210 protein~* One of the following:~  * Patient age 18 to 65~ * Disease duration longer than 3 years~ * Accelerated phase CML~* Accelerated phase diagnosis based on any of the following:~  * More than 10% to less than 30% blasts in blood or bone marrow~ * No hematologic response to prior conventional therapy (hydroxyurea or interferon)~ * Extramedullary disease (e.g., progressive splenomegaly or lymphadenopathy)~ * Basophilia greater than 10% in blood or bone marrow~ * Other cytogenetic abnormalities in addition to a single Ph chromosome~ * Second chronic phase~* Failure on interferon suggested of patients over age 18 with chronic phase CML, with failure defined as:~  * No detectable Ph-negative metaphases in marrow after 6 months~ * No progressive increase in Ph-negative metaphases in marrow after 6-12 months~ * Less than 50% Ph-negative metaphases after 1 year~ * No complete cytogenetic remission after 2 years~ * Intolerance to interferon therapy~* No blast crisis CML, chronic myelomonocytic leukemia, or juvenile CML~* The following conditions are allowed:~  * Leukocyte count abnormalities~ * Fibrosis~ * Anemia~ * Fever or bone pain~ * Thrombocytopenia~ * Bone marrow reticulin~* Availability of an HLA-identical sibling donor~  * At least 3 years of age (priority given to donors over age 10)~ * Priority given to CMV-negative donor if patient CMV-negative~ * No medical or psychiatric condition that precludes transplant procedure~PATIENT CHARACTERISTICS:~Age~* 18 to 65~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* See Disease Characteristics~Hepatic~* Not specified~Renal~* Not specified~Other~* No history of intolerance to sargramostim (GM-CSF)~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).